Survival after photodynamic therapy to non‐pulmonary metastatic endobronchial tumors
- 1 January 1999
- journal article
- research article
- Published by Wiley in Lasers in Surgery and Medicine
- Vol. 24 (3) , 194-201
Abstract
For the past 15 years we have used photodynamic therapy (PDT) to treat endobronchial tumors. Unfortunately patients who have non-primary lung cancer metastatic to bronchi and who have failed other treatment regimens may not be offered endobronchial tumor management. Thirteen patients with endobronchial tumors metastatic from non-pulmonary primaries were treated with PDT. We: 1) evaluated the effects of PDT on the tumor, the quality of life, and the length of survival; and 2) compared their survival after PDT to that of 27 patients with stage IV primary endobronchial tumors treated with PDT after they failed all other treatment regimens. Photodynamic therapy was performed using 630-nm light delivered through cylinder diffusing tip quartz fibers passed through the biopsy channel of a flexible bronchoscope after intravenous injection of the photosensitizer dihematoporphyrin ether. One to two days after PDT bronchoscopy was repeated and necrotic tissue was mechanically removed and, if necessary, that site or other new sites were treated. Two days after this another bronchoscopy was performed and the necrotic tissue was mechanically removed. Bronchoscopy was repeated one month after PDT and periodically thereafter as needed to re-treat symptomatic residual tumor. The percent obstruction of the bronchus due to tumor was estimated before and at the end of each bronchoscopy. Clinical effects were evaluated using Wilcoxon signed rank tests for scaled parameters of dyspnea, cough, hemoptysis, and Karnofsky Performance Status (KPS) before and one month after PDT. All patients were followed until their death. The mean percent obstruction due to metastatic non-pulmonary tumors at 38 different endobronchial treated sites decreased from 85% to 13% at discharge after PDT. The 72% mean decrease of obstruction was statistically significant using the Wilcoxon signed rank test (P < .0001). There was a statistically significant improvement in the level of dyspnea (P = .012), hemoptysis (P = .028), cough (P = .027), and KPS (P = .020). Kaplan-Meier survival curves and Mann-Whitney U rank tests showed the median survival of stage IV primary tumor patients (4 months) vs. metastatic tumor patients (14 months) was statistically significant (P = .008). PDT of endobronchial metastatic tumors effectively decreased the amount of endobronchial obstruction, and improved the quality of life.Keywords
This publication has 9 references indexed in Scilit:
- Endobronchial photodynamic therapy for hemoptysis1994
- Endobronchial metastasisThe Journal of Thoracic and Cardiovascular Surgery, 1993
- Metastatic Leiomyosarcoma of the Uterus: Unusual Presentation of a Case with Late Endobronchial and Small Bowel MetastasesGynecologic Oncology, 1993
- Endobronchial Metastases in Colorectal AdenocarcinomaTumori Journal, 1992
- Surgical management of pulmonary metastatic leiomyosarcoma with gross endobronchial extensionThe Annals of Thoracic Surgery, 1990
- Endobronchial Metastases due to Colorectal CarcinomaChest, 1989
- OXYGEN LIMITATION OF DIRECT TUMOR CELL KILL DURING PHOTODYNAMIC TREATMENT OF A MURINE TUMOR MODELPhotochemistry and Photobiology, 1989
- Endobronchial metastases from soft tissue sarcomaJournal of Surgical Oncology, 1986
- Breast cancer and thoracic metastases: review of 119 patients.Thorax, 1983